|
Chugai Pharmaceutical develops therapies for bone metabolism and blood disorders, cancer, infectious diseases, immune system disorders, and cardiovascular, kidney, and brain diseases. Products include Neutrogin, which treats white blood cell loss related to chemotherapy; Epogin, which treats red blood cell loss caused by chronic kidney failure; Sigmart, an antianginal agent; and Alfarol for osteoporosis. Chugai Pharmaceuticals has foreign operations in Asia, Europe, and North America through subsidiaries and branch locations. Swiss drugs group Roche owns about 60% of Chugai Pharmaceutical.
|
| | | Contact Information | |
Address: |
1-1 Nihonbashi-Muromachi 2-chome, Chuo-ku
Tokyo 103-8324, Japan
| | Phone: | +81-3-3281-6611 | | Fax: | +81-3-3281-2828 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2007): | 3069.10 M | | Revenue Growth (1 yr): | 12.10% |
|
|
Key People
| | • |
President, CEO, COO, and Director:
Osamu Nagayama
| | • |
Deputy President, Corporate Social Responsibility, Technolog:
Motoo Ueno
| | • |
EVP and CFO, System and Corporate Communications and Directo:
Ryuzo Kodama
|
|
|
